PKU HealthCare (SZ:000788) Xin Lang Cai Jing·2025-10-31 01:37Core Insights - The company reported a total revenue of 1.231 billion yuan for Q3 2025, a decrease of 303 million yuan compared to the same period last year, representing a year-on-year decline of 19.76% [1] - The net profit attributable to shareholders was 136 million yuan, with net cash inflow from operating activities amounting to 132 million yuan [1] Financial Performance - The latest debt-to-asset ratio stands at 23.09% [3] - The gross profit margin is 27.03%, ranking 128th among disclosed peers, down by 0.73 percentage points from the same period last year [3] - Return on equity (ROE) is 8.42%, a decrease of 0.06 percentage points year-on-year [3] - The diluted earnings per share (EPS) is 0.23 yuan [3] - The total asset turnover ratio is 0.56 times, down by 0.08 times from the previous year, reflecting a year-on-year decline of 12.86% [3] - The inventory turnover ratio is 5.40 times, a decrease of 0.25 times compared to the same period last year, representing a decline of 4.40% [3] Shareholder Structure - The number of shareholders is 49,400, with the top ten shareholders holding a total of 222 million shares, accounting for 37.30% of the total share capital [3] - The top shareholders include: 1. Southwest Synthetic Pharmaceutical Group Co., Ltd. - 22.2% 2. Peking University Medical Management Co., Ltd. - 11.81% 3. Chen Jinggeng - 0.68% 4. Beijing Zhengquan Holdings Co., Ltd. - 0.54% 5. Wang Lugui - 0.46% 6. China Construction Bank Co., Ltd. - 0.38% 7. Yuan Xiufeng - 0.33% 8. Liu Shanghong - 0.33% 9. Liu Zhixiong - 0.29% 10. Yiyuan - 0.27% [3]